Major
Established
描述
Valproic acid doubles lamotrigine plasma concentrations by inhibiting its glucuronidation; the combination is associated with Stevens-Johnson syndrome and toxic epidermal necrolysis.
机制
Valproic acid inhibits UGT1A4 and UGT2B7, the primary enzymes for lamotrigine glucuronidation, substantially reducing lamotrigine clearance and elevating systemic exposure.
临床意义
The risk of life-threatening skin reactions (SJS/TEN) is significantly increased; the FDA mandates a slower lamotrigine titration schedule when co-prescribed with valproate.
处理措施
Use the specific lamotrigine titration schedule for valproate co-therapy (half the usual starting dose and titration rate); monitor skin closely.